Alimera Sciences, which is developing an injectable implant to treat eye diseases, raised $72 million by offering 6,550,000 shares at $11.00, below the range of $15.00 to $17.00. Alimera Sciences plans to list on the NASDAQ under the symbol ALIM. Credit Suisse and Citi acted as joint book-running managers on the deal.
